Drug Profile
Elranatamab - Pfizer
Alternative Names: Elranatamab-bcmm; ELREXFIO; Elrexfio; ELREXFIOTM; PF-06863135; PF‑3135; RN-613Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Multiple myeloma
Most Recent Events
- 26 Mar 2024 Registered for Multiple myeloma (Second-line therapy or greater) in Japan (SC)
- 08 Mar 2024 Pfizer initiates a phase I trial for Multiple myeloma (Second-line therapy or greater) in USA (SC) (NCT06138275)
- 28 Feb 2024 PETHEMA Foundation plans a phase II trial for Multiple Myeloma (Second-line therapy or greater) in Spain (SC, Injection)(NCT06282978)